Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs: flufenamic acid and its 5-chloro-derivative directly interact with a recombinant human myeloperoxidase to inhibit the synthesis of hypochlorous acid.
Van Antwerpen P, Dufrasne F, Lequeux M, Boudjeltia KZ, Lessgyer I, Babar S, Moreau P, Moguilevsky N, Vanhaeverbeek M, Ducobu J, Nève J. Van Antwerpen P, et al. Among authors: moguilevsky n. Eur J Pharmacol. 2007 Sep 10;570(1-3):235-43. doi: 10.1016/j.ejphar.2007.05.057. Epub 2007 Jun 12. Eur J Pharmacol. 2007. PMID: 17610876
Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors.
Van Antwerpen P, Legssyer I, Zouaoui Boudjeltia K, Babar S, Moreau P, Moguilevsky N, Vanhaeverbeek M, Ducobu J, Nève J. Van Antwerpen P, et al. Among authors: moguilevsky n. Eur J Pharmacol. 2006 May 10;537(1-3):31-6. doi: 10.1016/j.ejphar.2006.03.022. Epub 2006 Mar 20. Eur J Pharmacol. 2006. PMID: 16631159
Glycosylation pattern of mature dimeric leukocyte and recombinant monomeric myeloperoxidase: glycosylation is required for optimal enzymatic activity.
Van Antwerpen P, Slomianny MC, Boudjeltia KZ, Delporte C, Faid V, Calay D, Rousseau A, Moguilevsky N, Raes M, Vanhamme L, Furtmüller PG, Obinger C, Vanhaeverbeek M, Nève J, Michalski JC. Van Antwerpen P, et al. Among authors: moguilevsky n. J Biol Chem. 2010 May 21;285(21):16351-9. doi: 10.1074/jbc.M109.089748. Epub 2010 Mar 23. J Biol Chem. 2010. PMID: 20332087 Free PMC article.
Myeloperoxidase-dependent LDL modifications in bloodstream are mainly predicted by angiotensin II, adiponectin, and myeloperoxidase activity: a cross-sectional study in men.
Boudjeltia KZ, Delporte C, Van Antwerpen P, Franck T, Serteyn D, Moguilevsky N, Raes M, Vanhamme L, Vanhaeverbeek M, Van Meerhaeghe A, Roumeguère T. Boudjeltia KZ, et al. Among authors: moguilevsky n. Mediators Inflamm. 2013;2013:750742. doi: 10.1155/2013/750742. Epub 2013 Nov 18. Mediators Inflamm. 2013. PMID: 24347830 Free PMC article.
Triggering of inflammatory response by myeloperoxidase-oxidized LDL.
Boudjeltia KZ, Legssyer I, Van Antwerpen P, Kisoka RL, Babar S, Moguilevsky N, Delree P, Ducobu J, Remacle C, Vanhaeverbeek M, Brohee D. Boudjeltia KZ, et al. Among authors: moguilevsky n. Biochem Cell Biol. 2006 Oct;84(5):805-12. doi: 10.1139/o06-061. Biochem Cell Biol. 2006. PMID: 17167545
Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis.
Van Antwerpen P, Néve J, Moreau P, Boudjeltia KZ, Vanhaeverbeek M, Prévost M, Babar S, Legssyer I, Moguilevsky N, Ducobu J. Van Antwerpen P, et al. Among authors: moguilevsky n. J Cardiovasc Pharmacol. 2007 Sep;50(3):350-1. doi: 10.1097/FJC.0b013e31809501dc. J Cardiovasc Pharmacol. 2007. PMID: 17878766 No abstract available.
83 results